A Multiplex Panel of Plasma Markers of Immunity and Inflammation in Classical Kaposi Sarcoma

被引：8

作者：

Aka, Peter V. ^{[1
]}

Kemp, Troy J. ^{[1
]}

Rabkin, Charles S. ^{[1
]}

Shiels, Meredith S. ^{[1
]}

Polizzotto, Mark N. ^{[2
]}

Lauria, Carmela ^{[3
]}

Vitale, Francesco ^{[4
]}

Pinto, Ligia A. ^{[1
]}

Goedert, James J. ^{[1
]}

机构：

[1] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[2] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, Bethesda, MD 20892 USA

[3] Lega Italiana Lotta Contro & Tumori Sez Ragusa, Ragusa, Italy

[4] Univ Palermo, Dipartimento Sci Promoz Salute & Materno Infantil, I-90133 Palermo, Italy

来源：

JOURNAL OF INFECTIOUS DISEASES | 2015年 / 211卷 / 02期

基金：

美国国家卫生研究院;

关键词：

classical Kaposi sarcoma; IP-10; sIL-1RII; human herpesvirus 8; RISK-FACTORS;

D O I：

10.1093/infdis/jiu410

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Kaposi sarcoma (KS) risk is affected by perturbed immunity. Herein, we compared plasma from 15 human immunodeficiency virus (HIV)-negative classic KS cases to plasma from 29 matched controls, using a multiplex panel of immunity markers. Of 70 markers, CXCL10 (IP-10), sIL-1RII, sIL-2RA, and CCL3 (MIP-1A) were strongly and significantly associated with KS, after adjustment for age and smoking status. These and previous observations are consistent with a tumor-promoting role for these cytokines, particularly CXCL10, but the small sample size and case-control design preclude firm conclusions on KS risk or pathogenesis. Larger, well-designed prospective studies are needed to better assess the association of these markers with KS.

引用

页码：226 / 229

页数：4

共 16 条

[1] Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily [J].

Amodio, Emanuele ;

Goedert, James J. ;

Barozzi, Patrizia ;

Riva, Giovanni ;

Firenze, Alberto ;

Bonura, Filippa ;

Viviano, Enza ;

Romano, Nino ;

Luppi, Mario .

CANCER SCIENCE, 2011, 102 (10) :1769-1773

[2] Risk Factors for Classical Kaposi Sarcoma on a Population-based Case-control Study in Sicily [J].

Anderson, Lesley A. ;

Lauria, Carmela ;

Romano, Nino ;

Brown, Elizabeth E. ;

Whitby, Denise ;

Graubard, Barry I. ;

Li, Yan ;

Messina, Angelo ;

Gafa, Lorenzo ;

Vitale, Francesco ;

Goedert, James J. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (12) :3435-3443

[3] Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma [J].

Brown, Elizabeth E. ;

Whitby, Denise ;

Vitale, Francesco ;

Marshall, Vickie ;

Mbisa, Georgina ;

Gamache, Christine ;

Lauria, Carmela ;

Alberg, Anthony J. ;

Serraino, Diego ;

Cordiali-Fei, Paola ;

Messina, Angelo ;

Goedert, James J. .

CANCER, 2006, 107 (09) :2282-2290

[4] Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity [J].

Brown, Elizabeth E. ;

Fallin, Daniele ;

Ruczinski, Ingo ;

Hutchinson, Amy ;

Staats, Brian ;

Vitale, Francesco ;

Lauria, Carmela ;

Serraino, Diego ;

Rezza, Giovanni ;

Mbisa, Georgina ;

Whitby, Denise ;

Messina, Angelo ;

Goedert, James J. ;

Chanock, Stephen J. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (05) :926-934

[5] Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lyric replication [J].

Chang, J ;

Renne, R ;

Dittmer, D ;

Ganem, D .

VIROLOGY, 2000, 266 (01) :17-25

[6] Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study [J].

Chaturvedi, Anil K. ;

Kemp, Troy J. ;

Pfeiffer, Ruth M. ;

Biancotto, Angelique ;

Williams, Marcus ;

Munuo, Stella ;

Purdue, Mark P. ;

Hsing, Ann W. ;

Pinto, Ligia ;

McCoy, J. Philip ;

Hildesheim, Allan .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (09) :1902-1911

[7] Kaposi's Sarcoma-Associated Herpesvirus-G Protein-Coupled Receptor-Expressing Endothelial Cells Exhibit Reduced Migration and Stimulated Chemotaxis by Chemokine Inverse Agonists [J].

Couty, Jean-Pierre ;

Lupu-Meiri, Monica ;

Oron, Yoram ;

Gershengorn, Marvin C. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 329 (03) :1142-1147

[8] Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens [J].

Goto, Naoe ;

Tsurumi, Hisashi ;

Goto, Hideko ;

Shimomura, Yoriko Ino ;

Kasahara, Senji ;

Hara, Takeshi ;

Yasuda, Ichiro ;

Shimizu, Masahito ;

Murakami, Nobuo ;

Yoshikawa, Takeshi ;

Fukuno, Kenji ;

Takahashi, Takeshi ;

Kito, Yusuke ;

Takami, Tsuyoshi ;

Moriwaki, Hisataka .

ANNALS OF HEMATOLOGY, 2012, 91 (05) :705-714

[9] Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment [J].

Lewis, Anne M. ;

Varghese, Sheelu ;

Xu, Hui ;

Alexander, H. Richard .

JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)

[10] Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma [J].

Little, Richard F. ;

Pluda, James M. ;

Wyvill, Kathleen M. ;

Rodriguez-Chavez, Isaac R. ;

Tosato, Giovanna ;

T Catanzaro, Andrew ;

Steinberg, Seth M. ;

Yarchoan, Robert .

BLOOD, 2006, 107 (12) :4650-4657

← 1 2 →